Notably, among individuals with non-DNMT3A-driven CH, IL-6 levels increased to a lesser extent in those receiving colchicine vs. placebo over 1 year (30.0% vs. 98.1% increase, respectively; p for interaction = 0.01). Here, IL6 is linked to cyclic hematopoiesis.